Al­loy and Pyx­is spin out new 'com­pa­ny' around high-risk I/O, im­munol­o­gy tar­gets

When CEO Lara Sul­li­van and the team at Pyx­is sat down in 2019 to see which of the many tar­gets from Thomas Gajew­s­ki’s im­muno-on­col­o­gy lab they would try to drug, there were too many for any start­up to pur­sue at once. They pri­or­i­tized the tar­gets they thought had the best chance of suc­cess, leav­ing the rest for some fu­ture date.

That date came soon­er than ex­pect­ed. Last year, the team at Al­loy Ther­a­peu­tics —the con­glom­er­ate of biotech ser­vices, tech­nolo­gies and spin­outs backed by bil­lion­aire in­vestor Pe­ter Thiel — got wind of all that Pyx­is was leav­ing on the ta­ble. Now, the two are spin­ning out a new com­pa­ny, Ky­ma Ther­a­peu­tics, ded­i­cat­ed to find­ing an­ti­bod­ies that can hit two of the high-risk tar­gets, po­ten­tial­ly open­ing up paths to treat­ments in can­cer and im­munol­o­gy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER